drug discovery

Jan 30, 2025

Norlase Received FDA 510(k) Clearance and CE Mark for LYNX™ Indirect Laser Ophthalmoscope with Pattern Tracking On January 27, 2025, Norlase, a leading global manufacturer of ophthalmic lasers developing next-generation laser solutions, announced the commercial launch and receipt of FDA 510(k) clearance and CE M...

Mar 14, 2024

MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment On March 12, 2024, Mangoceuticals, Inc. unveiled a groundbreaking development eagerly awaited by many: the launch of 'PRIME' by MangoRx, Powered by Kyzatrex®️. This release mar...

Nov 01, 2023

Molecular modeling, a revolutionary branch of science that seeks to understand and manipulate the intricate world of molecules at the atomic and molecular levels, has seen a remarkable transformation in recent years, owing to the growth in technology. The union of computational science, chemistry, and biology has g...

Mar 01, 2023

Next-Generation Sequencing (NGS) or commonly referred to as deep sequencing or massively parallel sequencing, is an important field of sequencing technology applied to determine the RNA or DNA sequence. It aims to provide detailed information about the genetic variation in organisms, diseases, or other biological p...

Jun 18, 2019

Bluebird declares the price of its gene therapy- Zynteglo Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approx...

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Sep 19, 2018

Novo Nordisk set to restructure R&D business Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark and China. It is done so that the expansion is accelerated and its pipeline across serious chronic diseases is diversi...